News

As per the new deal, Agios will receive a $20m payment and Celgene will have exclusive option to drug candidates generated by Agios’ cancer metabolism research platform during

Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties. The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 patients with relapsing forms of MS and showed

The GRF peptide is said to have the similar potency and efficacy as that of tesamorelin and is shorter than it. Tesamorelin is an analogue of the human

The trial will evaluate the efficacy of BioCancell’s BC-819 in sequence with Gemcitabine, in treating locally-advanced, unresectable pancreatic cancer. pbpb About 100 participants are expected to be enrolled

NITD received a library of compounds that will be screened in a cell-based assay to identify molecules that are active against the TB causing mycobacterium from CDRI. As

The software will be implemented by the pharma company for its commercial teams in the five largest European countries. The tool, developed to cater to the needs of

Stephen Key will lay emphasis on pharmaceutical applications for prescription, over-the-counter, nutritional supplements, injectable vials and vitamins. Stephen Key Design is specialized in Spinformation rotating label technology with

ClinicalTrials.gov provides updated information on federally and privately supported clinical trials for a wide range of diseases and conditions. Currently, the database comprises 113,224 sponsored trials conducted in

UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM which is caused due to sialic acid deficiency. The company initiated